Latest glioblastoma Stories
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
Results Presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology MIAMI, Nov.
Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
VAL-083 Anti-tumor Activity Is Consistently Superior to Temozolomide in Preclinical Models of Glioblastoma VANCOUVER, British Columbia, MENLO PARK, Calif., and MIAMI, Nov.
Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Interim analysis of the pivotal phase III trial of Tumor Treating Fields in newly diagnosed glioblastoma (EF-14) will be presented as a late-breaking oral presentation ST.
HEIDELBERG, Germany, Oct.
In-demand research report “Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM”
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has received a $1Million grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.